Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: The MYBL2–CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages

Fig. 2

MYBL2 transcriptionally activates CCL2 expression. (A) Gene Ontology term analyses of significantly differentially expressed genes in the shMYBL2 group compared with the vector control group. (B) Venn diagram of genes involved in the leukocyte chemotaxis pathway and significantly differentially expressed genes. Quantitative PCR (C), ELISA (D), immunofluorescence (E), and western blotting (F) were used to detect CCL2 expression. (G-H) CHIP assay to identify the possible binding site of MYBL2 on the CCL2 promoter. (I-K) Relative luciferase activities of different reporters containing wild-type or mutant sequences of the CCL2 promoter in the indicated cells

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us